JB
LRMR icon

Julian Baker’s Larimar Therapeutics LRMR Stock Holding History

Julian Baker’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-32,529
Closed -$12.5M – 134
2015
Q3 		$12.5M Buy
32,529
+8,556
+36% +$3.86M 0.12% 55
2015
Q2 		$9.96M Buy
23,973
+16,078
+204% +$6.73M 0.09% 63
2015
Q1 		$3.75M Buy
+7,895
New +$3.75M 0.03% 85

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Julian Baker's LRMR Position: Q4 2015 in Review

Julian Baker sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 32,529 shares — an estimated $12.5M sold.

Julian Baker first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $12.5M in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Julian Baker reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Julian Baker sold 32,529 Larimar Therapeutics shares in Q4 2015, an estimated $12.5M.
  • Julian Baker first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
  • Julian Baker's Larimar Therapeutics position peaked at $12.5M in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.